Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12487959 | 1.00 | TGM2 (0.72) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL9779379 | 1.00 | TGM2 (0.72) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL3728729 | 0.98 | HTT (0.70) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL646561 | 0.94 | HTT (0.72) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL9874334 | 0.92 | HTT (0.79) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL9340146 | 0.92 | HTT (0.79) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL15346534 | 0.92 | HTT (0.79) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL18254066 | 0.91 | HTT (0.81) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL6447301 | 0.88 | HTT (0.72) | TGM2HTTLMNASMN1; SMN2KEAP1 | |
| SCHEMBL7877730 | 0.88 | HTT (0.72) | TGM2HTTLMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110825-B1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT LTD (IN) | 2020-12-09 | — | — | EP | claimed |
| US-10183962-B2 | Synthetic oligomers of Neisseria meningitis serogroup X and process of preparing them | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD. (IN) | 2019-01-22 | — | — | US | claimed |
| EP-3110825-B1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT LTD (IN) | 2020-12-09 | — | — | EP | disclosed |
| US-10183962-B2 | Synthetic oligomers of Neisseria meningitis serogroup X and process of preparing them | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD. (IN) | 2019-01-22 | — | — | US | disclosed |
| US-20170066794-A1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD. (IN) | 2017-03-09 | — | — | US | disclosed |
| EP-3110825-A1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. (IN) | 2017-01-04 | — | — | EP | disclosed |
| CN-105797168-A | Compositions and method for treatment of autoimmune and other diseases | 天蓝制药公司 | 2016-07-27 | — | — | CN | disclosed |
| US-20160185881-A1 | Oligosaccharide Compounds | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2016-06-30 | — | — | US | disclosed |
| US-9315587-B2 | Oligosaccharide compounds | VICTORIA LINK LIMITED (NZ) | 2016-04-19 | — | — | US | disclosed |
| WO-2015128797-A1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD. (IN) | 2015-09-03 | — | — | WO | disclosed |
| US-20140051659-A1 | Oligosaccharide Compounds | THE UNIVERSITY OF LIVERPOOL (GB) | 2014-02-20 | — | — | US | disclosed |
| US-RE34722-E | Antiulcer agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| WO-1994014775-A1 | PLATELET AGGREGATION INHIBITING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994014776-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994012478-A1 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-09 | — | — | WO | disclosed |
| EP-0600092-A1 | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0593603-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-04-27 | — | — | EP | disclosed |
| WO-1993000095-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-07 | — | — | WO | disclosed |
| EP-0460679-A2 | Endothelin antagonistic peptide derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-4578381-A | ANTIULCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185881-A1 | Oligosaccharide Compounds | BACE1, BACE2, ENGASE | TGM2 1287/4885HTT 212/4885LMNA 1239/4885 |
| US-20170066794-A1 | NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM | MLEC, MEN1, MAN2B2 | TGM2 2736/4885HTT 1516/4885LMNA 1102/4885 |
| US-10183962-B2 | Synthetic oligomers of Neisseria meningitis serogroup X and process of preparing them | MLEC, MEN1, MAN2B2 | TGM2 2465/4885HTT 1397/4885LMNA 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.